Table 5.
Process and outcome indicators related to specific conditions
n (%) | |
---|---|
Prevention of postpartum hemorrhage | |
Target population: women giving birth in health care facilities | 1,001 |
Oxytocin use | 79.5 |
Use of any uterotonic (including oxytocin) | 29.7 |
Treatment of severe postpartum hemorrhage | |
Target population: women with severe postpartum hemorrhage | 46 |
Oxytocin use | 39 (84.8) |
Ergometrine | 0 |
Misoprostol | 11 (10.6) |
Any of the above uterotonics | 39 (84.6) |
Tranexamic acid | 0 |
Removal of retained products | 1 (0.96) |
Balloon or condom tamponade | 1 (0.96) |
Artery ligation | 0 |
Hysterectomy | 12 (11.5) |
Abdominal packing | 0 |
Anticonvulsants for eclampsia | |
Target population: women with eclampsia | 19 |
Magnesium sulfate | 16 (84.2) |
Other anticonvulsant | 0 |
Any anticonvulsant | 16 (84.2) |
Prevention of cesarean section-related infection | |
Target population: women undergoing cesarean section | 45 |
Prophylactic antibiotic during cesarean section | 39 (86.7) |
Treatment for sepsis | |
Target population: women with sepsis | 18 |
Parenteral therapeutic antibiotics | 15 (83.3) |
Ruptured uterus | |
Target population: women with ruptured uteri | 9 |
Laparotomy | 8 (88.9) |
Laparotomy after 3 hours of hospital stay | 3 (33.3) |
Preterm birth | |
Target population: women having a preterm delivery | 22 |
Corticosteroids for fetal lung maturation | 8 (36.4) |